Childhood neuroblastoma is often a fatal disease. A new approach using a combination of two drugs shows promise in reducing ...

The FDA approved the investigational new drug application for a phase 1 trial of ADCE-T02 in advanced solid tumors.

Adcendo, a biotech company pioneering the development of first and best-in-class ADCs for cancers with a high unmet medical ...

Datroway demonstrated durable antitumor activity and an acceptable safety profile in advanced NSCLC with actionable genomic ...

"The goal is to expand treatment options for HER2-mutant NSCLC, which is currently a challenging and prognostically ...

HER2 (also known as ERBB2) is a key oncogene in breast cancer and is found in 2–4% of patients with non-small-cell lung ...

Akeso begins patient enrolment in phase I trial of AK138 D1 for the treatment of advanced malignancies in Australia: Hong Kong Saturday, March 1, 2025, 12:00 Hrs [IST] Akeso, Inc.

Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that the first patient has been successfully dosed in the Phase III ...

Introduction Antitumor antibiotics are a class of chemotherapy drugs derived from natural sources, primarily Streptomyces bacteria, and are wid ...

在肿瘤研究的浩瀚征程中，科学家们从未停止探索的脚步。肿瘤的特征之一是不受控制的细胞分裂，并在此过程中伴随着DNA复制、细胞周期蛋白的表达和激活、微管蛋白重组等细胞活动。一些小分子抑制剂，例如DNA烷化和交联剂、CDK抑制剂等可以高效地阻断上述过程，进 ...

Researchers led by Prof. TONG Minghan from the Center for Excellence in Molecular Cell Science of the Chinese Academy of Sciences, collaborating with Prof. HUANG Ying from Xinhua Hospital, Shanghai ...

HONG KONG, Feb. 27, 2025 /PRNewswire/ -- Akeso, Inc. (9926) announced the first patient has been enrolled in the Phase I clinical trial of AK138 D1 for the treatment of advanced malignancies in ...